Drug Trial Radar · NCT06492460
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
422
Planned (sponsor's estimate)
Start
Sep 20, 2024
Primary completion
Sep 20, 2029
Study completion Jul 17, 2033
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hunan Cancer Hospital; Guilin Medical University, China; Jiangsu Cancer Institute & Hospital; Xiangya Hospital of Central South University
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this trial was to determine the value of 2 courses of cisplatin concurrent chemotherapy in postoperative adjuvant radiotherapy for high-risk head and neck squamous cell carcinoma.
Conditions
- Squamous Cell Carcinoma of Head and Neck
Interventions
Drug:CisplatinDrug
Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Failure-free survival (FFS)Time frame: 3 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Affiliated Hospital of Guilin Medical College
Guilin, Guangxi, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
Xiangya Hospital, Central South University
Changsha, Hunan, China · Not yet recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.